Beta-blockers in heart failure - A cardioprotective therapy?

Journal of Clinical Pharmacy and Therapeutics

Volumn 22, Issue 3, 1997, Pages 181-185

  Landray, M J ^a,b   Kendall, M J ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; MILRINONE; XAMOTEROL;

CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HEART PROTECTION; HEMODYNAMICS; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; REVIEW;

EID: 0031451571     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1997.9775097.x     Document Type: Review

References (38)

1. The SOLVD Investigators. (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine, 325, 293-302.
2. Doll R. (1988) Epidemiology - the prevention of cancer; some recent developments. Journal of Cancer Research and Clinical Oncology, 114, 447-458.
3. Hasking GJ, Esler MD, Jennings GL, et al. (1986) Norepinephrine spill over to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation, 73, 615-621.
4. Leimbach WN, Wallin G, Victor RG, et al. (1986) Direct evidence from intraneuronal recordings for increased central sympathetic outflow in patients with heart failure. Circulation, 73, 913-919.
5. Thomas JA, Marks BH. (1978) Plasma norepinephrine in congestive heart failure. American Journal of Cardiology, 41, 233-242.
6. Cohn JN, Levine TB, Olivari MT, et al. (1984) Plasma norepinephrine as aguide to prognosis in patients with chronic congestive heart failure. New England Journal of Medicine, 311, 819-823.
7. Ertl G, Neubauer S, Gaudron P, et al. (1994) Beta-blockers in cardiac failure. European Heart Journal, 15(Suppl. C), 16-24.
8. Wit AL, Hoffmann BF, Rosen MR. (1975) Electrophysiology and pharmacology of cardiac arrhythmias IX: Cardiac electrophysiologic effects of beta-adrenergic receptor stimulation and blockade - Part A. American Heart Journal 90, 521-533.
9. 1-receptor down-regulation in heart failure. Circulation Research, 59, 297-309.
10. Asseman P, McFadden E, Bauclart J-J, Loubeyre C, Thery C. (1994) Why do β-blockers help in idiopathic dilated cardiomyopathy-frequency mismatch? Lancet, ii, 803-804.
11. Andersson B, Blomstrom-Lundquist C, Hedner T, Waagstein F. (1991) Exercise haemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. Journal of the American College of Cardiology, 18, 1059-1066.
12. Heilbrunn SM, Shah P, Bristow MR, et al. (1989) Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation, 79, 483-490.
13. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson A. (1989) Long-term beta-blockade in congestive cardiomyopathy. Effects of acute and chronic metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation, 80, 551-563.
14. 1-adrenergic receptor up regulation? Circulation, 70(Suppl II), 112.
15. Buhler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR. (1972) Propranolol inhibition of renin secretion: A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. New England Journal of Medicine, 287, 1209-1214.
16. Townend JN, Vaile J, Coote JH. (1995) Preventing sudden cardiac death: the impact of beta-blockers on the brain. Journal of Clinical Pharmacy and Therapeutics, 20, 307-310.
17. Ablad B, Bjuro T, Bjorkman J-A, Edstrom T, Olsson G. (1991) Role of central nervous beta-adrenoceptors I. The prevention of ventricular fibrillation through augmentation of cardiac vagal tone. Journal of the American College of Cardiology, 17, 165.
18. Goldsmith RL, Krun H, Bigger JT Jr, Bloomfield D, Packer M. (1993) Beta-blockade increases parasympathetic activity in chronic heart failure. Circulation, 88(Suppl. I), 103.
19. Schramm MS, Marks ML, Olsen SL, Gilbert EM. (1993) Chronic β-blocker therapy with carvedilol increases parasympathetic drive in heart failure. Circulation, 88(Suppl. I), 104.
20. Townend JN, Littler WA. (1995) Cardiac parasympathetic control: a target for intervention? Lancet, 345, 937-938.
21. Di Lenarda A, Gilbert EM, Olsen SL, Mealey PC, Bristow MR. (1991) Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 17, 142 A.
22. Landray MJ, Kendall MJ. (1997) Coronary artery disease and antioxidants - is there a role for carvedilol? Journal of Clinical Pharmacy and Therapeutics, 22, 3-5.
23. Maggi E, Marchesi E, Covini D, et al. (1996) Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low-density lipoprotein oxidation in essential hypertension. Journal of Cardiovascular Pharmacology, 27, 532-538.
24. Sung C-P, Arleth AJ, Ohlstein EH. (1993) Carvedilol inhibits vascular smooth muscle cell proliferation. Journal of Cardiovascular Pharmacology, 21, 221.
25. Waagstein F, Bristow MR, Swedberg K, et al. (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet, 342, 1441-1446.
26. Andersson B, Lomsky M, Waagstein F. (1993) The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. European Heart Journal, 14, 1375-1385.
27. Australia/New Zealand Heart Failure Research Collaborative Group. (1997) Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet, 349, 375-380.
28. CIBIS Investigators and Committees. (1994) A randomized trial of β-blockade in heart failure. Circulation, 90, 1765-1773.
29. Packer M, Bristow MR, Cohn JN, et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New England Journal of Medicine, 334, 1349-1355.
30. Packer M, Carver JR, Rodeheffer RJ, et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. New England Journal of Medicine, 325, 1468-1475.
31. The Xamoterol in Severe Heart Failure Study Group. (1990) Xamoterol in severe heart failure. Lancet, 336, 1-6. [Erratum (1990) Lancet, 336, 698.]
32. The Digitalis Investigation Group. (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine, 336, 525-533.
33. Doughty RN, Rodgers A, Sharpe N, MacMahon S. (1997) Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. European Heart Journal, 18, 560-565.
34. β-Blocker Heart Attack Trial Research Group. (1982) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. Journal of the American Medical Association, 247, 1707-1714.
35. The Norwegian Multicenter Study Group. (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine, 304, 801-807.
36. The SOLVD Investigators. (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine, 327, 685-691.
37. The CONSENSUS Trial Study Group. (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine, 316, 1429-1435.
38. Cohn JN, Johnson G, Ziesche S, et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine, 325, 303-310.